Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer HealthCare to present hypertension drug data at ACCP meeting

Bayer HealthCare to present hypertension drug data at ACCP meeting

18th October 2012

Bayer HealthCare has announced plans to present data on a new hypertension therapy at Chest 2012, the forthcoming annual congress of the American College of Chest Physicians (ACCP).

Phase III trial results will be discussed at the Atlanta event that demonstrate the potential efficacy of Bayer HealthCare's riociguat as a treatment for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (CTEPH).

Riociguat is the first member of a novel class of compounds that is able to stimulate an enzyme called soluble guanylate cyclise in a way that results in a dual mode of action.

Its potential use as a therapy for CTEPH is particularly important, as there is currently no licensed pharmacological therapy available for this disease.

Kemal Malik, member of the Bayer HealthCare executive committee and head of global development, said: "It is our aim to address the unmet needs of pulmonary hypertension by providing innovative medicines."

Earlier this month, the company agreed a new alliance with Evotec that will see the organisations carrying out joint research into endometriosis therapies.ADNFCR-8000103-ID-801471702-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.